gms | German Medical Science

68. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS)

17.09. - 21.09.23, Heilbronn

ETL Processes for Supporting Evidence-Based Therapy Recommendations in Oncology – System and Architecture

Meeting Abstract

  • Mahmoud Sharf - Institut für Medizinische Informatik, Universitätsklinikum Heidelberg, Heidelberg, Germany
  • Carolin Plöger - Zentrum für Personalisierte Medizin Heidelberg, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Germany
  • Katrin Schneider - Zentrum für Personalisierte Medizin Heidelberg, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Germany
  • Martin Dugas - Institut für Medizinische Informatik, Universitätsklinikum Heidelberg, Heidelberg, Germany
  • Angela Merzweiler - Institut für Medizinische Informatik, Universitätsklinikum Heidelberg, Heidelberg, Germany
  • Fleur Fritz-Kebede - Institut für Medizinische Informatik, Universitätsklinikum Heidelberg, Heidelberg, Germany

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie. 68. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS). Heilbronn, 17.-21.09.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocAbstr. 273

doi: 10.3205/23gmds041, urn:nbn:de:0183-23gmds0417

Veröffentlicht: 15. September 2023

© 2023 Sharf et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: Medical experts continuously seek to cope with the rapid development of new effective therapy plans. This goal becomes an increasing challenge when targeting chronic diseases like cancer, where many factors should be observed simultaneously to identify the most effective treatments for each case. Besides, healthcare insurance companies seek to examine the clinical evidence of cancer treatments before accepting medical claims. Therefore, a medical information system is needed to provide personalised clinical decision support for Molecular Tumor Board (MTB) experts in cancer care [1] and generating new medical evidence for new treatment options. In this work, we present a technical implementation for a data integration solution to realize such a system using Extract-Transform-Load(ETL) processes to integrate clinically valuable and diverse, multi-source data of cancer patients, including their therapy plans, into a single data model to support an evidence-based clinical decision making.

Methods: Our solution starts with defining the clinical data to be integrated (input) and the target schema (output). First, the data model for both input and output schemas should be defined carefully, and then a mapping from input to output schemas is documented accordingly. Regarding input, we receive both clinical and genetic patient data documented by the Institute of Pathology of Heidelberg University Hospital and exported from the Onkostar system [2] in xml format. Afterwards, the ETL pipelines are built in Talend data integration platform to integrate input data into an output repository in json format following the target schema. Afterwards, the integrated data of all patients can be queried to provide the required evidence-based clinical decision support.

Results: The ETL pipelines are already developed, tested, and set as productive for the regular processing and integration of oncology patients' data for the ZPM project [3], [4] with a complex structure of 200+ data elements distributed among 30 data objects with multiple levels of data hierarchy (up to 3 levels of nested loops). This project seeks to establish a network between regional university hospitals for an aggregated collection of oncology data in the state of Baden-Württemberg, which is referred to as bwHealthCloud (bwHC) [3]. As for April 2023, oncological data for > 300 patients has been already integrated into bwHC. This integrated data is available for therapy planning, evidence-based communication between clinics, and research studies.

Discussion: The implemented data integration solution for investigating evidence-based medical treatments and conducting clinical research is technically feasible, and can be reproduced and transferred to other clinics that use the Onkostar documentation system. However, this solution is limited to the Onkostar-specific XML input schema. In the future, we plan to integrate data from different input schemas of other documentation systems by mapping the data first into an intermediary staging database, where data can be stored in a tabular structured format. Afterwards, these structured data can be mapped to the target schema. The data platform is currently extended from a regional (bwHC) to a nationwide (DNPM:dip) level [5]. Besides oncology, this approach can be also generalized to advance evidence-based personalized medicine in other medical use cases.

The authors declare that they have no competing interests.

The authors declare that an ethics committee vote is not required.


References

1.
VanderWalde A, Grothey A, Vaena D, Vidal G, ElNaggar A, Bufalino G, Schwartzberg L. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med. 2020 Nov 27;10(4):252. DOI: 10.3390/jpm10040252 Externer Link
2.
onkostar.de [Internet]. Modern tumor documentation system for oncology. Available from: https://www.onkostar.de/ Externer Link
3.
zpm-verbund.de [Internet]. Zentren für Personalisierte Medizin (ZPM), also referred to as Baden-Württemberg Health Cloud (bwHC). Available from: https://zpm-verbund.de/de/ueber-die-zpm/zpm-verbund/ Externer Link
4.
Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavelier L, Schirmacher P, Malek N, Rosenquist R; GMS working group and ZPM working group. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2022 Sep;84:242-254. DOI: 10.1016/j.semcancer.2021.05.026 Externer Link
5.
dnpm.de [Internet]. Das Deutsche Netzwerk für Personalisierte Medizin (DNPM). Available from: https://dnpm.de/ Externer Link